Management ChangeApr 14, 2026, 06:06 AM
ImmuCell Board Sees 3 Directors Depart, Elects 2 New Members
AI Summary
ImmuCell Corporation announced significant changes to its Board of Directors, with three long-serving members, Bryan K. Gathagan, Michael F. Brigham, and Bobbi Jo Brockmann, retiring or resigning effective April 15, 2026. Michael F. Brigham had served as President and CEO for over 25 years. Concurrently, the Board elected Gilles Guillemette, DVM, and Anthony DiMarco, Ph.D., as new directors, effective the same date, bringing extensive executive and scientific leadership experience in animal and human health.
Key Highlights
- Three directors, including former CEO Michael F. Brigham, to depart the Board.
- Michael F. Brigham served as CEO for over 25 years and Director since 1999.
- Two new directors, Gilles Guillemette and Anthony DiMarco, elected to the Board.
- Dr. Guillemette brings over 30 years and Dr. DiMarco over 40 years of industry experience.
- Dr. Guillemette will chair a new Strategy & Technology Committee.